glp-1 agonists diabetes GLP1 Receptor Agonists—Effects beyond Obesity and Evolution of GLP‐1 Receptor Agonists

Target Trial Emulation Using Real World Data In the present study, researchers emulated a target trial assessing associations between different GLP-1RA treatment scenarios and MACE risk

In this experiment, the high protein diet can promote intestinal secretion of GLP-1, improve FGF21 resistance, upregulate LKB1 to activate the AMPK pathway, downregulate the expression of SERBP-1c mRNA and protein in the liver, and ultimately inhibit liver lipid synthesis [50]

Glucagonlike peptide-1(7-36)amide suppresses glucagon secretion and decreases cyclic AMP concentration in cultured In-R1-G9 cells

Treatment with 3 mg liraglutide for 20 weeks reduced appetite and energy intake, resulting in a significant weight loss (7.2 kg) in a large, RCT in people with obesity [15]

For patients, the studys message is simple but urgent: not all GLP-1 offerings are built the same way